[
  {
    "ts": null,
    "headline": "Stocks to Watch Friday Recap: Intel, GM, Ford",
    "summary": "↗️ Intel (INTC): President Trump said late Thursday he had \"just finished a great meeting\" with CEO Lip-Bu Tan. Shares leapt 11% Friday. The U.S. has said it will convert around $9 billion in federal grants into a 10% equity stake in the chip maker.",
    "url": "https://finnhub.io/api/news?id=8d9ec8d37cc937080e30e173c7aa1fa86c823dc3a87a24dfe09a2fbb19dccced",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767984555,
      "headline": "Stocks to Watch Friday Recap: Intel, GM, Ford",
      "id": 138050548,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "↗️ Intel (INTC): President Trump said late Thursday he had \"just finished a great meeting\" with CEO Lip-Bu Tan. Shares leapt 11% Friday. The U.S. has said it will convert around $9 billion in federal grants into a 10% equity stake in the chip maker.",
      "url": "https://finnhub.io/api/news?id=8d9ec8d37cc937080e30e173c7aa1fa86c823dc3a87a24dfe09a2fbb19dccced"
    }
  },
  {
    "ts": null,
    "headline": "J&J Finds Middle Ground in Washington",
    "summary": "Drug discounts trade for tariff relief",
    "url": "https://finnhub.io/api/news?id=3482878ca6b8474dddac06bf75f680a8d7217160576474f658c2e59c3a37e31f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767980999,
      "headline": "J&J Finds Middle Ground in Washington",
      "id": 138052218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Drug discounts trade for tariff relief",
      "url": "https://finnhub.io/api/news?id=3482878ca6b8474dddac06bf75f680a8d7217160576474f658c2e59c3a37e31f"
    }
  },
  {
    "ts": null,
    "headline": "Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN)",
    "summary": "Legend Biotech Corporation (NASDAQ:LEGN) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On December 17, Cantor Fitzgerald maintained its Overweight rating on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $74. The firm said the stock has come under pressure because of concerns about competition, even though […]",
    "url": "https://finnhub.io/api/news?id=0ac6e2836e71f7aa83f988b077bb7a0a131b0de223989c4a4bf87849427ebabf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767978458,
      "headline": "Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN)",
      "id": 138052219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Legend Biotech Corporation (NASDAQ:LEGN) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On December 17, Cantor Fitzgerald maintained its Overweight rating on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $74. The firm said the stock has come under pressure because of concerns about competition, even though […]",
      "url": "https://finnhub.io/api/news?id=0ac6e2836e71f7aa83f988b077bb7a0a131b0de223989c4a4bf87849427ebabf"
    }
  },
  {
    "ts": null,
    "headline": "2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio",
    "summary": "Add some stability to your holdings with these healthcare giants.",
    "url": "https://finnhub.io/api/news?id=f9da08e5e2a8b2b0eb10caa1a88927bea2c28de4bdc041de0fdf50896272f3b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767978300,
      "headline": "2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio",
      "id": 138052220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Add some stability to your holdings with these healthcare giants.",
      "url": "https://finnhub.io/api/news?id=f9da08e5e2a8b2b0eb10caa1a88927bea2c28de4bdc041de0fdf50896272f3b6"
    }
  },
  {
    "ts": null,
    "headline": "How Are Legal Risks And Ortho Spinoff Shaping The Johnson & Johnson (JNJ) Narrative Now",
    "summary": "What Is Driving the Updated Fair Value Estimate? The new fair value estimate for Johnson & Johnson has edged from about US$209.29 to about US$211.38 per share, a small shift that reflects a slightly higher revenue growth assumption at about 5.34% while the discount rate stays essentially unchanged at about 6.96%. This fine tuning lines up with recent Street commentary that highlights above consensus Q3 results, confidence in the product pipeline, and expectations that the planned orthopedics...",
    "url": "https://finnhub.io/api/news?id=f7d50b76e371fc22fd9d1a5ddb41f292e6ab8b2dce1d463d5d84e0ecc1e84f75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767975271,
      "headline": "How Are Legal Risks And Ortho Spinoff Shaping The Johnson & Johnson (JNJ) Narrative Now",
      "id": 138052221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "What Is Driving the Updated Fair Value Estimate? The new fair value estimate for Johnson & Johnson has edged from about US$209.29 to about US$211.38 per share, a small shift that reflects a slightly higher revenue growth assumption at about 5.34% while the discount rate stays essentially unchanged at about 6.96%. This fine tuning lines up with recent Street commentary that highlights above consensus Q3 results, confidence in the product pipeline, and expectations that the planned orthopedics...",
      "url": "https://finnhub.io/api/news?id=f7d50b76e371fc22fd9d1a5ddb41f292e6ab8b2dce1d463d5d84e0ecc1e84f75"
    }
  },
  {
    "ts": null,
    "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
    "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
    "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767973860,
      "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
      "id": 138052210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
      "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca"
    }
  },
  {
    "ts": null,
    "headline": "Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress",
    "summary": "Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.",
    "url": "https://finnhub.io/api/news?id=4559c69b1cbfff8b3efecea539c44cfabc032b0bbc97ed6d74324fdfcff066a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767968220,
      "headline": "Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress",
      "id": 138046638,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.",
      "url": "https://finnhub.io/api/news?id=4559c69b1cbfff8b3efecea539c44cfabc032b0bbc97ed6d74324fdfcff066a2"
    }
  },
  {
    "ts": null,
    "headline": "Can da Vinci 5 Expand Intuitive Surgical's TAM Beyond Core Surgeries?",
    "summary": "ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.",
    "url": "https://finnhub.io/api/news?id=9f0ada614bd8274eb02d11f07d8bb271bfc5a48c4000e0e2190929799427090c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767968160,
      "headline": "Can da Vinci 5 Expand Intuitive Surgical's TAM Beyond Core Surgeries?",
      "id": 138046639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.",
      "url": "https://finnhub.io/api/news?id=9f0ada614bd8274eb02d11f07d8bb271bfc5a48c4000e0e2190929799427090c"
    }
  },
  {
    "ts": null,
    "headline": "Here's What We Expect From AbbVie's Immunology Segment in Q4",
    "summary": "ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.",
    "url": "https://finnhub.io/api/news?id=09b911cafe130d129e73462fa37b066d995c4dce1085f38c82dc1a5f6a7d8e29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767962640,
      "headline": "Here's What We Expect From AbbVie's Immunology Segment in Q4",
      "id": 138045462,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.",
      "url": "https://finnhub.io/api/news?id=09b911cafe130d129e73462fa37b066d995c4dce1085f38c82dc1a5f6a7d8e29"
    }
  },
  {
    "ts": null,
    "headline": "HSBC lists 11 potential U.S. outperformers heading into earnings",
    "summary": "Investing.com -- HSBC has identified 11 U.S. stocks that could outperform as the fourth-quarter earnings season begins, highlighting companies with strong competitive positions, improving fundamentals and exposure to long-term themes.",
    "url": "https://finnhub.io/api/news?id=983d3d6c8707e8d88a1c351006017098b04fad71beb43cb0151e6547efb9c3fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767961731,
      "headline": "HSBC lists 11 potential U.S. outperformers heading into earnings",
      "id": 138045471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing.com -- HSBC has identified 11 U.S. stocks that could outperform as the fourth-quarter earnings season begins, highlighting companies with strong competitive positions, improving fundamentals and exposure to long-term themes.",
      "url": "https://finnhub.io/api/news?id=983d3d6c8707e8d88a1c351006017098b04fad71beb43cb0151e6547efb9c3fc"
    }
  },
  {
    "ts": null,
    "headline": "J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts",
    "summary": "The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.",
    "url": "https://finnhub.io/api/news?id=d54018c88b87e3d0d35e24ac04c699e68ebb10724d1fa2df4c3d059d2427aae1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767961410,
      "headline": "J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts",
      "id": 138045475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.",
      "url": "https://finnhub.io/api/news?id=d54018c88b87e3d0d35e24ac04c699e68ebb10724d1fa2df4c3d059d2427aae1"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Preview: What to Expect From Kenvue’s Report",
    "summary": "Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.",
    "url": "https://finnhub.io/api/news?id=263e7ff6d85be31ce2f96b871dd256d856ae2aba85a90375f6c857a67d49ffdf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767959714,
      "headline": "Earnings Preview: What to Expect From Kenvue’s Report",
      "id": 138046640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.",
      "url": "https://finnhub.io/api/news?id=263e7ff6d85be31ce2f96b871dd256d856ae2aba85a90375f6c857a67d49ffdf"
    }
  },
  {
    "ts": null,
    "headline": "Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal",
    "summary": "Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.",
    "url": "https://finnhub.io/api/news?id=cd30537d2698b702d9f948de455a87c310a75485b5e316e12cf07881a09b9c57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767958080,
      "headline": "Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal",
      "id": 138052212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.",
      "url": "https://finnhub.io/api/news?id=cd30537d2698b702d9f948de455a87c310a75485b5e316e12cf07881a09b9c57"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Friday: Intel, GM, Rio Tinto, Glencore",
    "summary": "↗️ Intel (INTC): President Trump said late Thursday he had \"just finished a great meeting\" with Intel CEO Lip-Bu Tan. The chipmaker's shares gained 2.5% in premarket trading. The U.S. has said it will convert around $9 billion in federal grants into a 10% equity stake in Intel.",
    "url": "https://finnhub.io/api/news?id=2873f85e71a0a69b2e778ae58f77fcd4087d13ae861bae79deacd056b000ee53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767956608,
      "headline": "Stocks to Watch Friday: Intel, GM, Rio Tinto, Glencore",
      "id": 138045476,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "↗️ Intel (INTC): President Trump said late Thursday he had \"just finished a great meeting\" with Intel CEO Lip-Bu Tan. The chipmaker's shares gained 2.5% in premarket trading. The U.S. has said it will convert around $9 billion in federal grants into a 10% equity stake in Intel.",
      "url": "https://finnhub.io/api/news?id=2873f85e71a0a69b2e778ae58f77fcd4087d13ae861bae79deacd056b000ee53"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, Caterpillar, Qualcomm, Fossil and Jones Soda",
    "summary": "Johnson & Johnson is gaining momentum as innovative medicines and a strengthening MedTech business support growth despite key patent headwinds.",
    "url": "https://finnhub.io/api/news?id=aef25aea98935185b487dde904115f96b2dbc827d902b48a8420a3b73525a25c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767954180,
      "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, Caterpillar, Qualcomm, Fossil and Jones Soda",
      "id": 138045477,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson is gaining momentum as innovative medicines and a strengthening MedTech business support growth despite key patent headwinds.",
      "url": "https://finnhub.io/api/news?id=aef25aea98935185b487dde904115f96b2dbc827d902b48a8420a3b73525a25c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Strikes Deal With White House to Lower Drug Prices",
    "summary": "Johnson & Johnson  has said it will lower the price of some medications sold to U.S. consumers, making it the latest pharmaceutical company to form a business agreement with the Trump administration.  “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” Johnson & Johnson’s chief executive Joaquin Duato said in a statement late Thursday.  Johnson & Johnson also said it will participate in the proposed patient platform, TrumpRx.gov, which will allow patients to buy drugs at “significantly discounted rates.”",
    "url": "https://finnhub.io/api/news?id=e7f42c4b24d63a7e1512cb192d4418f2b5964d578781bfe65390f3d46123700e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767953400,
      "headline": "Johnson & Johnson Strikes Deal With White House to Lower Drug Prices",
      "id": 138045478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson  has said it will lower the price of some medications sold to U.S. consumers, making it the latest pharmaceutical company to form a business agreement with the Trump administration.  “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” Johnson & Johnson’s chief executive Joaquin Duato said in a statement late Thursday.  Johnson & Johnson also said it will participate in the proposed patient platform, TrumpRx.gov, which will allow patients to buy drugs at “significantly discounted rates.”",
      "url": "https://finnhub.io/api/news?id=e7f42c4b24d63a7e1512cb192d4418f2b5964d578781bfe65390f3d46123700e"
    }
  },
  {
    "ts": null,
    "headline": "Cramer’s Mad Dash: Johnson & Johnson",
    "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
    "url": "https://finnhub.io/api/news?id=423ded9896d24222ac9a85e5d17f51b543b677baabab13b2d31e8415b3595223",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767952044,
      "headline": "Cramer’s Mad Dash: Johnson & Johnson",
      "id": 138047619,
      "image": "https://image.cnbcfm.com/api/v1/image/108250504-17679694901767969488-43410881465-1080pnbcnews.jpg?v=1767969489&w=1920&h=1080",
      "related": "JNJ",
      "source": "CNBC",
      "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
      "url": "https://finnhub.io/api/news?id=423ded9896d24222ac9a85e5d17f51b543b677baabab13b2d31e8415b3595223"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to cut US drug prices, secures tariff exemption",
    "summary": "Johnson & Johnson to cut US drug prices, secures tariff exemption",
    "url": "https://finnhub.io/api/news?id=e6616fde97f4b8af5a8cd8e1261e503361bddf3821792a88bdf702b979a8631d",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767929772,
      "headline": "Johnson & Johnson to cut US drug prices, secures tariff exemption",
      "id": 138041631,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e6616fde97f4b8af5a8cd8e1261e503361bddf3821792a88bdf702b979a8631d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices",
    "summary": "The agreement provides Johnson & Johnson’s pharmaceutical products an exemption from tariffs, the company said.",
    "url": "https://finnhub.io/api/news?id=2105a27b418521ad6ddeeee2f7c05e2340783b77d5978eb1fa059f31f8dc4564",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767925980,
      "headline": "Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices",
      "id": 138043076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The agreement provides Johnson & Johnson’s pharmaceutical products an exemption from tariffs, the company said.",
      "url": "https://finnhub.io/api/news?id=2105a27b418521ad6ddeeee2f7c05e2340783b77d5978eb1fa059f31f8dc4564"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson reaches deal with US government to lower drug prices",
    "summary": "Jan 8 () - Johnson & ​Johnson ‌said on Thursday ‌it has reached a ⁠agreement ‌with U. President ‍Donald Trump's administration to ​cut ‌drug prices for Americans in exchange ⁠for exemptions ​from ​U.",
    "url": "https://finnhub.io/api/news?id=a64d6f30590320189cf91371d953164b97afb265ad759f92c52ca8003dc075f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767923064,
      "headline": "Johnson & Johnson reaches deal with US government to lower drug prices",
      "id": 138043077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Jan 8 () - Johnson & ​Johnson ‌said on Thursday ‌it has reached a ⁠agreement ‌with U. President ‍Donald Trump's administration to ​cut ‌drug prices for Americans in exchange ⁠for exemptions ​from ​U.",
      "url": "https://finnhub.io/api/news?id=a64d6f30590320189cf91371d953164b97afb265ad759f92c52ca8003dc075f4"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments",
    "summary": "NEW BRUNSWICK, N.J., January 09, 2026--Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.",
    "url": "https://finnhub.io/api/news?id=5e79a8f5f42c23e1d3bd4bf425b45c31cf001e9aae4c47972cf323f71af90ac1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767921840,
      "headline": "Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments",
      "id": 138043078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW BRUNSWICK, N.J., January 09, 2026--Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.",
      "url": "https://finnhub.io/api/news?id=5e79a8f5f42c23e1d3bd4bf425b45c31cf001e9aae4c47972cf323f71af90ac1"
    }
  }
]